Drug Trial Radar · NCT03836287
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Last checked: Nov 20, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Oct 9, 2020
Primary completion
Jun 25, 2021
Study completion Jun 25, 2021
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.
Conditions
- Axillary Hyperhidrosis
Interventions
Sofpironium Bromide Gel, 15%Drug
Active
VehicleDrug
Vehicle gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
- Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, P.C.
Birmingham, Alabama
Investigate MD, LLC
Scottsdale, Arizona
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas
California Dermatology & Clinical Research Institute
Encinitas, California
Dermatology Research Associates
Los Angeles, California
Therapeutics Clinical Research
San Diego, California
Clinical Science Institute
Santa Monica, California
AboutSkin Research, LLC
Greenwood Village, Colorado
Center for Clinical & Cosmetic Research
Aventura, Florida
Skin Care Research, LLC
Boca Raton, Florida
Skin Research Institute
Coral Gables, Florida
Finlay Medical Research
Greenacres City, Florida
Aby's New Generation Research
Hialeah, Florida
Baumann Cosmetic and Research Institute
Miami, Florida
International Dermatology Research, Inc.
Miami, Florida
My Community Research Center, Inc.
Miami, Florida
Tory Sullivan, MD PA
North Miami Beach, Florida
Research Institute of the Southeast
West Palm Beach, Florida
Dawes Fretzin Research Group
Indianapolis, Indiana
Maryland Laser Skin and Vein
Hunt Valley, Maryland
Lawrence J Green, MD LLC
Rockville, Maryland
SkinCare Physicians
Chestnut Hill, Massachusetts
Grekin Skin Institute
Warren, Michigan
Minnesota Clinical Study Center
New Brighton, Minnesota
MediSearch Clinical Trials
Saint Joseph, Missouri
Skin Specialists, P.C.
Omaha, Nebraska
Hassman Research Institute
Berlin, New Jersey
DermResearch Center of New York, Inc.
Stony Brook, New York
PMG Research of Cary
Raleigh, North Carolina
Haber Dermatology and Cosmetic Surgery, Inc.
Beachwood, Ohio
Oregon Dermatology & Research Center
Portland, Oregon
Clinical Research Center of the Carolinas
Charleston, South Carolina
Tennessee Clinical Research Center
Nashville, Tennessee
DermResearch, Inc.
Austin, Texas
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas
Progressive Clinical Research
San Antonio, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Virginia Clinical Research, Inc.
Norfolk, Virginia
Dermatology Associates of Seattle
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.